Industry veteran brings 20+ years of commercial leadership to accelerate Genomenon’s expansion in the RWE market
ANN ARBOR, MICH. - November 20, 2025 - FOR IMMEDIATE RELEASE
Genomenon®, Inc., an AI-driven genomics company, today announced the appointment of Kristin Fix as Senior Vice President of Sales. With more than two decades of experience building and leading commercial organizations in Life Sciences - including senior executive roles at Inovalon and Symphony Health, Fix will lead Genomenon’s global sales strategy as the company scales its leadership in the rapidly growing literature-derived Real-World Evidence (RWE) market.
Historically, RWE has largely meant electronic health records (EHR), registry, and claims data. Genomenon takes a different approach - using AI and expert curation to systematically extract and structure patient-level evidence from the scientific literature into clean, clinically relevant datasets that illuminate how patients actually present, progress, and respond to treatment. This literature-derived real-world evidence fills the gaps left by EHR and claims data, giving rare disease and oncology teams the complete genomic and phenotypic context needed to design better trials, strengthen regulatory packages, and expand the reach of targeted therapies.
With more than 75 RWE programs delivered for over 25 pharmaceutical partners, Genomenon’s literature-derived platform is already informing indication strategy, patient cohort discovery, and evidence generation. Fix’s leadership will further accelerate the company’s expansion with top-tier pharma and biopharma organizations, leveraging her deep domain expertise and proven track record of scaling data-driven solutions.
“Kristin has repeatedly demonstrated how to bring high-value data and evidence solutions to market, build accountable sales cultures, and scale organizations that deliver real results,” said Mike Klein, CEO of Genomenon. “She understands the language of pharma and her experience aligns perfectly with where we’re taking the company.”
Prior to joining Genomenon, Fix served as SVP of Insights Sales at Inovalon, where she led commercial teams, advanced channel partner strategies, and delivered integrated data and commercialization solutions for life sciences clients. She also held executive sales leadership roles at Symphony Health, consistently driving growth across data and analytics offerings. Her background in data analytics, managed markets, training, and product strategy positions her to lead Genomenon’s next phase of growth in literature- derived RWE.
“I’m thrilled to join Genomenon at this pivotal moment,” said Kristin Fix. “The combination of Genomenon’s genomic intelligence platform and its commitment to delivering structured, actionable real-world evidence is exactly what the industry needs. I’m excited to help our pharma partners unlock the full potential of literature-derived RWE and translate it into smarter decisions and faster innovation.”
About Genomenon
Genomenon is a bio-medical intelligence company transforming patient care and drug discovery by uncovering the drivers of disease and cancer. By combining large scale AI with expert human curation, the Genomenon converts the data in unstructured published research into clean, clinically relevant datasets that illuminate how patients actually present, progress, and respond to treatment, Genomenon delivers these structured, actionable insights to support advanced genomic diagnosis and accelerate precision medicine development. Its integrated software, data, and services solutions empower biopharma and clinical diagnostic partners worldwide.
Learn more at www.genomenon.com or follow us on LinkedIn.
Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world’s premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon's integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development.
